Mayo Center for Cell Signaling in Gastroenterology

梅奥胃肠病学细胞信号转导中心

• 批准号: 10200779
• 负责人: Nicholas F. LaRusso
• 金额: $ 117.98万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10200779
• 关键词: Cell Communication; Cells; Clinic; Clinical; Clinical Trials; Collaborations; Diagnosis; Digestive System Disorders; Direct Costs; Discipline; Disease; Educational Curriculum; Educational workshop; Enteral; Environment; Epigenetic Process; Equipment; Faculty; Feedback; Focus Groups; Fostering; Funding; Gastroenterology; Gastrointestinal Diseases; Genes; Genetic; Goals; Grant; Growth; Health; Inflammation; Infrastructure; Interdisciplinary Study; Investigation; Investments; Knowledge; Lead; Liver; Manuscripts; Mentorship; Methodology; Microscopy; Midwestern United States; Monitor; National Institute of Diabetes and Digestive and Kidney Diseases; Neurosciences; Optics; Pathogenesis; Pathway interactions; Patient Care; Patients; Peer Review; Prevention; Productivity; Public Health; Publications; Reagent; Research; Research Personnel; Research Support; Research Training; Resources; Science; Scientific Advances and Accomplishments; Scientist; Services; Signal Pathway; Signal Transduction; Structure; Technology; Technology Transfer; Therapeutic; Translations; Update; Visit; base; career development; cell transformation; cellular imaging; collaborative environment; cost; cost effective; epigenomics; gastrointestinal; health care service utilization; imaging capabilities; improved; innovation; interest; member; multidisciplinary; novel; patient oriented; practical application; programs; quality assurance; response; symposium; therapeutic target

PROJECT SUMMARY The overall objective of the Mayo Clinic Center for Cell Signaling in Gastroenterology (C-SiG) is to exploit signaling pathways in gastrointestinal cells to improve the health of patients with digestive diseases. To do this, C-SiG provides a robust infrastructure, thematic platforms, and career development opportunities to integrate and amplify impactful investigation along the discovery-translation-application paradigm. Our Research Base now consists of 68 scientists (15% growth) involving 18 departments and $23.7 million (direct costs, 2.5% growth) in digestive disease-related funding. Responding to members' evolving interests and scientific advances, we've re-aligned members into three interconnected Mechanistic Research Themes (intracellular signaling, cell-to-cell communication, and genetics/epigenetics), each intersecting with three Disease Focus Groups (liver pathobiology, enteric neurosciences, inflammation/transformation), a matrix that fosters both discovery and disease relevant investigation. Our ongoing CENTRAL HYPOTHESIS is that advances in care of patients with digestive diseases requires a facilitative infrastructure supporting meaningful interactions among multidisciplinary scientists investigating cellular mechanisms, pathways, and therapeutic targets to enhance rapid translation of basic discoveries into clinical trials. Our OVERALL SPECIFIC AIMS are to: i) Foster multidisciplinary research by expanding technical and collaborative capabilities of established GI scientists and attracting investigators from other disciplines; ii) Identify and nurture new GI investigators via a peer-reviewed Pilot and Feasibility (P/F) Program including career development workshops, curricula, and structured mentorship (19/26, 73% of P/F recipients achieving federal funding); iii) Offer core-based specialized equipment, technologies, methodologies, reagents, and expertise (Optical Microscopy, Clinical, and Gene Editing and Epigenomics Cores), with continuous core menu updates, quality assurance and assessments, and project management oversight in response to member feedback; iv) Support a robust Enrichment Program; and v) Promote interactions between C-SiG with other NIDDK centers at Mayo (e.g., PKD Center) and existing DDRCCs, especially in the Midwest (i.e., Midwest DDRCC Alliance). Our global efforts have resulted in 215 manuscripts, with 56% percent intra- and 44% inter-thematic publications (70% involving two or more members). Importantly, we've made critical advances in understanding disease pathogenesis relevant to signal transduction, cell-to-cell communication and genetics/epigenetics, thereby identifying potential disease modifying targets.

项目摘要 马约胃肠病学细胞信号传导临床中心（C-SiG）的总体目标是利用 胃肠细胞中的信号通路，以改善消化系统疾病患者的健康。要执行此操作， C-SiG提供了强大的基础设施，主题平台和职业发展机会， 沿着“发现-翻译-应用”的范式扩大有影响力的调查。我们的研究基地 现在包括68名科学家（增长15%），涉及18个部门和2370万美元（直接成本， 2.5%增长）的消化系统疾病相关的资金。响应成员不断变化的兴趣和科学 进步，我们已经重新排列成三个相互关联的机制研究主题（细胞内 信号传导、细胞间通讯和遗传学/表观遗传学），每一个都与三种疾病交叉。 焦点小组（肝脏病理生物学，肠道神经科学，炎症/转化），一个矩阵， 促进发现和疾病相关调查。我们持续的中心假设是， 消化系统疾病患者护理的进步需要一个促进性的基础设施， 研究细胞机制、途径和治疗方法的多学科科学家之间的相互作用 目标是促进基本发现快速转化为临床试验。我们的总体具体目标是 ㈠通过扩大现有机构的技术和协作能力，促进多学科研究 GI科学家和吸引其他学科的研究人员; ii）确定和培养新的GI研究人员 通过同行评审的试点和可行性（P/F）计划，包括职业发展研讨会，课程， （19/26，73%的P/F接受者获得联邦资助）; 专门的设备、技术、方法、试剂和专业知识（光学显微镜，临床， 和基因编辑和表观基因组学核心），不断更新核心菜单，质量保证和 （四）支持健全的项目管理体系， v）促进C-SiG与马约的其他NIDDK中心之间的相互作用（例如， PKD中心）和现有的DDRCC，特别是在中西部（即，中西部DDRCC联盟）。我们的全球 这些努力产生了215份手稿，其中56%是专题内出版物，44%是专题间出版物 (70涉及两名或两名以上成员的百分比）。重要的是，我们在了解疾病方面取得了重大进展， 与信号转导、细胞间通讯和遗传学/表观遗传学相关的发病机制， 识别潜在的疾病修饰靶点。